Incidence and Patterns of Second Primary Malignancies Following Oral Cavity Cancers in a Prevalent Area of Betel-nut Chewing: A Population-based Cohort of 26 166 Patients in Taiwan

Chen, Ping Tsung; Kuan, Feng Che; Huang, Cih-En; Chen, Miao Fen; Huang, Shih How; Chen, Min Chi; Lee, Kuan Der

doi:10.1093/jjco/hyr152

Cited by 24 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Taiwan, head and neck squamous cell carcinoma (HNSCC) is a highly prevalent malignancy and is associated with the habit and common risk factor of betel nut chewing (1)(2)(3). Clinical therapies for HNSCC patients consist of multiple-modality treatment with surgery, radiation and multi-drug chemotherapy (4,5).…”

Section: Introductionmentioning

confidence: 99%

“…As evidenced by our results, EGCG/gefitinib combination treatment modulates anti-metastatic effects in an HNSCC culture system in vitro. 2 tissue culture flasks (TPP, Techno Plastic Products AG., Trasadingen, Switzerland) with DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin and grown at 37˚C in a humidified 5% CO 2 atmosphere and detached by 0.25% Trypsin/0.02% EDTA (38)(39)(40).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2

Chang

et al. 2012

Oncology Reports

View full text Add to dashboard Cite

Abstract. Human head and neck squamous cell carcinoma (HNSCC) is a major cause of cancer-related death during the last decade due to its related metastasis and poor treatment outcomes. Gefitinib (Iressa), a tyrosine kinase inhibitor has been reported to reduce the metastatic abilities of oral cancer. Previous studies have shown that epigallocatechin gallate (EGCG), a green tea polyphenol, possesses cancer chemopreventive and anticancer activity. However, the mechanisms involved in the suppression of invasion and metastasis of human oral cancer cells following co-incubation with gefitinib and EGCG remain poorly understood. In the present study, we attempted to investigate the synergistic effects of a combined treatment of gefitinib and EGCG in CAL-27 cells in vitro and to elucidate the underlying molecular mechanisms associated with the supression of cell migration and invasion. In the present study, we found that the individual treatments or the combined treatment of gefitinib and EGCG synergistically inhibited the invasion and migration of CAL-27 cells using Transwell invasion and wound-healing scratch assays, respectively. Similarly, gefitinib in combination with EGCG synergistically attenuated enzymatic activity and the protein expression of MMP-2 in CAL-27 cells. Furthermore, individual or combined treatment with EGCG and gefitinib suppressed the protein expression of p-EGFR and the phosphorylated protein levels of ERK, JNK, p38 and AKT and displayed inhibitory effects on metastatic ability of CAL-27 cells. Combined effects of EGCG and gefitinib-altered anti-metastatic actions for related gene expression were observed using DNA microarray analysis. Importantly, EGCG sensitizes CAL-27 cells to gefitinib-suppressed phosphorylation of epidermal growth factor receptor (EGFR in vitro. Taken together, our results suggest that the synergistic suppression of the metastatic ability of CAL-27 cells after EGCG and gefitinib individual or combined treatment are mediated through mitogen-activated protein kinase (MAPK) signaling. Our novel findings provide potential insights into the mechanism involved with synergistic responses of gefitinib and EGCG against the progression of oral cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2

Chang

et al. 2012

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…We cannot disprove or approve these data due to a very small number of such patients in our study. Only further studies with more samples could confirm or disprove literature claims that poorer lung cancer survival prognosis worsens other primary cancer treatment outcomes (9,10,12). Surgery for localized pulmonary lesions is necessary because it helps to differentiate primary from metastatic tumors.…”

Section: Discussionmentioning

confidence: 99%

“…4.2% of gastric cancer patients had a second malignancy and lung cancer was detected in 28.4% cases (1). Lung cancers account for 5% of second primary cancers after breast cancer (7) and 7.2% after oral cavity cancers (9). For the highest-risk subgroups of head and neck cancers, second primary cancers occur in 4% of patients per year (2).…”

Section: Introductionmentioning

confidence: 99%

Surgery for lung cancer as the second primary malignancy

Krasauskas¹,

Aškinis²,

Zaremba³

et al. 2013

AML

View full text Add to dashboard Cite

Following a successful treatment of the first oncological disease, the second malignancy can develop. This retrospective study was designed to evaluate the efficacy of surgical treatment results for patients with the second primary lung cancer (2PLC) depending on the site of the first primary tumor (1PT).Materials and methods. From 2005From to 2009 were treated in the Subdivision of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University, with lung cancer as the second primary malignancy. 29 patients (33%) underwent surgery: 17 pts (58.6%) -lobectomies, 2 pts (6.9%) -pneumonectomies, 9 pts (31%) -anatomical segmentectomies and 1 pt (3.5%) -bilobectomy. All lung resections were performed with lymph nodes dissection. We had neither major complications nor mortality 30 days after surgery. Stages of 2PLC were as follows: IA-B stage (st.) -19 pts (65.5%), IIA-B st. -7 pts (24.1%), and IIIA-IV st. -3 pts (10.3%). Lung cancer morphology was the following: squamous cell -11 pts (37.9%), adenocarcinoma -13 pts (44.8%), large cell carcinoma -4 pts (13.8%), small cell lung cancer -1 pt (3.5%). First primaries of the patients were as follows: larynx -6 pts (207%), lung -2 pts (6.9%), stomach -3 pts (10.3%), colon and rectum -4 pts (13.8%), kidney -4 pts (13.8%), prostate -4 pts (13.8%), breast -2 pts (6.9%), gynecology -2 pts (6.9%) and haematologic malignancies -2 pts (6.9%). According to 1PT localization patients were divided into 4 groups: airways, gastrointestinal, urology and other malignancies.Results. 1-and 3-year survival was 69% and 27.6% (60.9% and 30.4% for males; 27.6% and 16.7% for females). 3-year survival for the first primary cancer was 37.5% in urological cancers, 14.3% in gastrointestinal, 37.5% in airway cancers and 16.7% in other cancer cases. Survival by stage of 2PLC was as follows: IA-B st. -33.3%, IIA-B st. -28.6%, respectively. No patients survived for 3 years with IIIA-IV st. of 2 PLC. By morphology of 2 PLC there were adenocarcinoma cases in 14.3%, squamous cell carcinoma in 50.0%. One patient with small cell 2 PLC has lived so far.Conclusions. 1. The site of the first primary tumor is not a significant prognostic factor for surgical outcomes of the second primary lung cancer (p > 0.5). 2. Statistically significant survival rates did not differ by gender and histological type of 2PLC. 3. A statistically significant survival difference was obtained only between the patients with IA-IIB st. and IIIA-IV st. of 2PLC (p = 0.0013).

show abstract

“…Therefore, these data are used for monitoring the long-term trends, prevalence and incidence of cancer as well as the indicators used in healthcare evaluation. TCR data has also been used as a resource for cancer-related research in several studies on the uniqueness of the TCR database or other related databases, such as the National Health Insurance Research Database, clinical laboratory test results database and National Register of Deaths (3)(4)(5)(6)(7). Cancer databases in Taiwan are widely used and are rapidly growing.…”

Section: Introductionmentioning

confidence: 99%

Are hospital cancer caseloads related to the validity of staging data reported? A lesson from National Cancer Registry in Taiwan

Cheng

Chiang

Hsiao

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Objective: Data from the National Taiwan Cancer Registry have been widely used since 2002 to assess quality of health, but its quality of coding in cancer staging data has not been discussed. This study assessed the agreement rate for staging by site visit at medical institutes. Methods: In this retrospective chart review study, 392 cancer patients in year 2013 were randomly selected from 14 hospitals; the senior cancer registrar reviewers had compared each original chart with data from the Taiwan Cancer Registry to assess agreement rate for staging. The hospitals were classified into two groups on the basis of the number of cancer patients. The kappa (κ) statistic method and multiple regression analysis were used to compare among the medical institutes and qualified cancer registrars. Results: The agreement rate was high in pharynx, esophageal, rectal, breast and prostate cancers, and low in ovarian and other cancers for clinical and pathological staging. After adjustment for the experience of the qualified cancer registrar, low-caseload hospitals had a significantly lower clinical staging agreement rate than that of high-caseload hospitals. After controlling the hospital cancer caseloads the cancer registrar background becomes one of significant factor. That is long duration between a basic license to an advanced license exceeded 5 years, having lower agreement rate. Conclusions: The reliability of staging data in the Taiwan Cancer Registry is affected not only by the cancer type but also by the number of patients treated in hospital. Moreover, the experience of cancer registrar strongly influences agreement rate, especially in clinical staging.

show abstract

Incidence and Patterns of Second Primary Malignancies Following Oral Cavity Cancers in a Prevalent Area of Betel-nut Chewing: A Population-based Cohort of 26 166 Patients in Taiwan

Cited by 24 publications

References 33 publications

Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2

Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2

Surgery for lung cancer as the second primary malignancy

Are hospital cancer caseloads related to the validity of staging data reported? A lesson from National Cancer Registry in Taiwan

Contact Info

Product

Resources

About